Anticoagulant treatment;Antikoagulationsbehandling

Ugeskrift for Laeger

Volumn 162, Issue 9, 2000, Pages 1247-1252

  Nielsen, Jørn Dalsgaard ^a   Husted, Steen Elkjær ^a   Lassen, Jens Flensted ^a   Nielsen, Hans Kræmmer ^a   Winther Hansen, Kaj F ^a   Antonsen, Steen ^a   Jespersen, Jørgen ^a  

^a Amtssygehuset I Gentofte ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

ANTICOAGULANT THERAPY; BLEEDING; DENMARK; DRUG INDICATION; DRUG MARKETING; HEART ATRIUM FIBRILLATION; HUMAN; MAINTENANCE THERAPY; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

ANTICOAGULANTS; CYTOCHROME P-450 ENZYME SYSTEM; DENMARK; DRUG INTERACTIONS; DRUG UTILIZATION; HEMORRHAGE; HEPARIN; HUMANS; PATIENT EDUCATION; RISK FACTORS; VITAMIN K;

EID: 0034724007     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Mendelson G, Aronow WS. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc 1998; 46: 1423-4.
2. Comp PC. Coumarin-induced skin necrosis. Incidence, mechanisms, management and avoidance. Drug Saf 1993; 8: 128-35.
3. Crowther MA, Ginsberg JB, Kearon C, Harrison L, Johnson J, Massicotte MP et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159: 46-8.
4. Proceedings of the American College of Chest Physicians 5th Consensus on Antithrombotic Therapy. 1998. Chest 1998; 114 (suppl 5): 439-769.
5. Tait RC, Sefcick A. A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation. Br J Haematol 1998; 101: 450-4.
6. O'Reilly RA, Pool JG, Aggeler PM. Heriditary resistance to coumarin anticoagulant drugs in man and rats. Ann N Y Acad Sci 1968; 151: 913-31.
7. Oldenburg J, Quenzel EM, Hårbrecht V. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-4.
8. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
9. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333: 447-58.
10. Manucci PM. Genetic control of anticoagulation. Lancet 1999; 353: 688-9.
11. Smith JK, Aljazairi A, Fuller SH. INR elevation associated with diarrhea in a patient receiving warfarin. Ann Pharmacother 1999; 33: 301-4.
12. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
13. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657-62.
14. McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 13: 311-6.
15. Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81: 396-9.
16. Dalere GM, Coleman RW, Lum BL. A graphic nomogram for warfarin dosage adjustment. Pharmacotherapy 1999; 19: 461-7.
17. Poller L, Shiach CR, MacCallum PK, Johansen AM, Munster AM, Magalhaes A et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 1998; 352: 1505-9.
18. Körfer R, Körtke H. Early self controlled anticoagulation trial (ESCAT). I: Krian A, Matloff JM, Nicoloff DM, eds. Advancing the technology of bileaflet mechanical heart valves. Darmstadt: Steinkopff Verlag, 1998: 12-22.
19. Horstkotte D. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolys 1998; 5 (suppl 1): 19-24.
20. Bernardo A. Optimierung der Langzeit-Antikoagulation durch Patienten-Selbstmanagement. Hämostaseologie 1997; 17: 137-40.
21. Cromheecke M, Levi M, Colly L, de Mol BJM, Prins MH, Hurten BA et al. A randomized cross-over comparison between oral anti-coagulation self management and management by the thrombosis service in the Netherlands [abstract]. Thromb Haemost 1999; 82 (suppl): 218.
22. Watzke HH, Forberg E, Svolba G, Jimenez-Boj E. A prospective controlled trial comparing weekly self tasting and self dosing with the conventional management of patients on oral anticoagulant therapy [abstract]. Thromb Haemost 1999; 82 (suppl): 219.
23. Poller L, van den Besselaar AMHP, Jespersen J, van der Meer F, Preston FE, Tripodi A et al. Normalisation and standardisation of home protrombin time (PT) monitors [abstract]. Thromb Haemost 1999; 82 (suppl) : 548.
24. Steffensen FH, Kristensen K, Ejlersen E, Dahlerup JF, Sørensen HT. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997; 242: 497-503.
25. Jørgensen T, Danneskiold-Samsøe B, Godtfredsen J, Jespersen J - på vegne af NEMT og Nordkem's Projektgruppe. Antikoagulansbehandling i Norden - sammenfattende rapport. København: Dansk Sygehus Institut, 1994: 1-48.
26. Doble N, Baron JH. Anticoagulation control with warfarin by junior hospital doctors. J R Soc Med 1987; 80: 627.
27. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-7.
28. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet 1997; 350: 389-96.
29. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158: 1513-21.
30. Loewen P, Sunderji R, Gin K. The efficacy and safety of combination warfarin and ASA therapy: a systematic review of the literature and update of guidelines. Can J Cardiol 1998; 14: 717-26.
31. Wentzien TH, O'Reilly RA, Kearns PJ. Prospective evaluation of anticoagulant reversal with oral vitamin K1 while continuing warfarin therapy unchanged. Chest 1998; 114: 1546-50.
32. Sindet-Pedersen S, Ramström G, Bernvil S, Blombäck M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989; 320: 840-3.
33. Horten JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician 1999; 59: 635-46.
34. Johnson J, Turpie AGG. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin (dalteparin) [abstract]. Thromb Haemost 1999; 82 (suppl): 62.
35. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.